ALVR AlloVir

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Stifel 2025 Annual Healthcare Conference.

Details:

  • Type: Company presentation
  • Speakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical Officer
  • Date: Thursday, November 13, 2025
  • Time: 3:20 – 3:50pm ET
  • Location: Lotte New York Palace Hotel, New York, NY



Kalaris management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.

About Kalaris

Kalaris Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases with major unmet medical needs. Founded by renowned scientist Dr. Napoleone Ferrara, whose pioneering research led to the development of anti-VEGF therapy, the company is committed to advancing novel therapeutic approaches for patients with sight-threatening retinal conditions such as neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

For more information, visit .

Kalaris Therapeutics Investor Contact:

Corey Davis, Ph.D.

LifeSci Advisors, LLC







EN
30/10/2025

Underlying

ALVRAlloVir

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on AlloVir

 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris Reports Third Quarter 2025 Financial Results and Provides Busi...

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reportedby year end 2025 Phase 1b/2 Multiple Ascending Dose trial currently enrolling, intended to inform dose selection for potential Phase 3 development program; initial clinical data expected in 2H 2026  Recent significant corporate milestones include the selection of a CDMO, CFO hire, and opening of corporate headquarters Cash, cash equivalents and short-term investments of $77.0M as of September 30, 2025, expected to...

November 12, 2025 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief...

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer Highly experienced biopharma financial officer joins leadership team  CFO hire bolsters Kalaris’ leadership team and supports continued growth of the company as it enrolls its Phase 1b/2 study in treatment naïve nAMD patients PALO ALTO, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Matthew Gall, MB...

November 3, 2025 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

Kalaris to Present at Stifel 2025 Annual Healthcare Conference PALO ALTO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Stifel 2025 Annual Healthcare Conference. Details: Type: Company presentationSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Thursday, November 13, 2025Time: 3:20 – 3:50pm ET...

October 30, 2025 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascend...

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development program, with initial data expected in 2H 2026 TH103’s ongoing Phase 1a single ascending dose study remains on track for data to be reported in Q4 2025 PALO ALTO, Calif., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Kalari...

September 15, 2025 1 EN
 PRESS RELEASE
Free
ALVR ALLOVIR

Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose ...

Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and preliminary efficacy in nAMD patients receiving up to four initial monthly doses of TH103 Phase 1b/2 study to inform dose selection for potential Phase 3 development program, with initial data expected in 2H 2026 TH103’s ongoing Phase 1a single ascending dose study remains on track for data to be reported in Q4 2025 PALO ALTO, Calif., Sept. 15, 2025 (GLOBE NEWS...

September 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch